Quality by Design (QbD) is a well-known pharmaceutical industry strategy for enhancing production processes, including active pharmaceutical ingredients and medicinal products. Companies may get useful insights throughout development by employing QbD concepts to build the design space and select relevant process controls. This case study shows how Renejix a QbD strategy to address an analytical method challenge involving high-performance liquid chromatography (HPLC). The approach showed fluctuating retention periods of impurity peaks, making identification and quantification difficult. Furthermore, the reported lack of consistency prompted concerns about properly detecting impurity levels, which might impair the medication product’s safety, quality, identity, purity, and potency (SQIPP).
Similar Posts
Streamlined Clinical Supply Services: RxReach Direct-to-Patient
Direct-to-Patient Clinical Supply Services: Amid the surge in remote clinical studies, the imperative of facilitating direct-to-patient distribution of clinical supplies has gained…
Early Phase Development Using Integrated Solutions
A newly formed pharmaceutical company was creating a novel cardiometabolic drug, a new small molecule, that was in Phase 2a testing in…
Solutions for Drug Development
An array of advanced technologies at your disposal to address your molecule’s challenges and processing hurdles effectively, achieving the optimal dosage form.
Solid State Form Characterization for Drug Development
Characterizing an API’s different salt forms and polymorphs is an essential drug development task. The successful preclinical assessment and product development can…
Equipment Lists
Please check out the below links to access our list of equipments available at the respective locations1. Hauppauge, New York2. Islip, New…
Precision Formulation via Small Batch Optimization
It is typical to encounter a restricted number of APIs during the initial stages of drug development. This limitation hinders the swift…